Gynecologic Cancer

Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing my mind, body and soul.

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.

Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.

After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.

When I was diagnosed with stage 1A cervical cancer, I realized that life is short and I want to spend my time being the best version of myself.

From pro wrestling legend Sid Vicious dying of cancer to Nicole Eggert’s breast cancer update, here’s what’s happening in the oncology space this week.

Even when I didn’t feel like riding, brushing and grooming her kept my spirits up and provided a social outlet that wasn’t medically oriented.

Even though my wife became quadriplegic after her breast cancer progressed, our insurance still did not help us out, so I became her caregiver full-time.

The Food and Drug Administration approved Jemperli with carboplatin and paclitaxel for primary advanced or recurrent endometrial cancer.

Patients with advanced gynecologic cancer given IMNN-001 with presurgical chemotherapy tended to live nearly a year longer.

A novel antibody-drug conjugate received an investigational new drug application for patients with gynecologic and lung cancers.

Stereotactic ablative radiotherapy led to promising disease control in patients with metastatic gynecologic cancers, research showed.

Here are eight poems about my experience as a caregiver to my wife during her final days.

While I was receiving treatment for endometrial cancer, I received so much support from friends, coworkers and people from my church.

After leaving an unsupportive support group for ovarian cancer, I finally found my pillars of support.

For patients with endometrial cancer that is dMMR, the two new drug approvals lead to more options, with a new option for patients with pMMR disease, too.

The Food and Drug Administration issued six approvals for solid tumors in June, including thyroid, endometrial, colorectal, breast and ovarian cancers.

After my mom died at 50 years old, I was certain I wasn't going to reach 50. I'm glad I was wrong.

Having an unwavering cancer community on Facebook has given me strength, which all started after they sent a teal blanket to me.

Participating in research and leaning on advocacy organizations helped me through my rare cancer diagnosis.

Leaning on spiritual belief may strengthen patients' life purposes, but for many, it's common to temporarily loosen their grip on faith after a cancer diagnosis.

The FDA approved Imfinzi plus carboplatin and paclitaxel followed by Imfinzi alone in patients with primary advanced or recurrent dMMR endometrial cancer.